This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aleksic, N. Articles by Wu, K. K. Search for Related Content PubMed PubMed Citation Articles by Aleksic, N. Articles by Wu, K. K. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Medline Plus Health Information Coronary Artery Disease Related Collections Risk Factors Arterial thrombosis Acute coronary syndromes Epidemiology Genetics of cardiovascular disease

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:348.)
© 2002 American Heart Association, Inc.

Thrombosis

Factor XIIIA Val34Leu Polymorphism Does Not Predict Risk of Coronary Heart Disease

The Atherosclerosis Risk in Communities (ARIC) Study

Nena Aleksic; Chul Ahn; Yao-Wei Wang; Harinder Juneja; Aaron R. Folsom; Eric Boerwinkle; Kenneth K. Wu

From the Vascular Biology Research Center and Hematology Division (N.A., C.A., Y.-W.W., H.J., K.K.W.), University of Texas-Houston Medical School; the Division of Epidemiology (A.R.F.), School of Public Health, University of Minnesota, Minneapolis; and the Human Genetics Center (E.B.), University of Texas-Houston Health Science Center.

Reprint requests to Dr Kenneth K. Wu, Professor and Director, Division of Hematology, University of Texas-Houston Medical School, 6431 Fannin, MSB 5.016, Houston, TX 77030. E-mail Kenneth.K.Wu{at}uth.tmc.edu

Factor XIII catalyzes the cross-linking of fibrin. Cross-sectional studies have suggested that a common polymorphism site at residue 34 of the A subunit of factor XIII (FXIIIA) with a substitution of Leu for Val (FXIIIA Val34Leu) was associated with reduced coronary heart disease (CHD). This association has not been examined in prospective studies. Healthy subjects (n=15 792) were recruited from 4 US communities into the Atherosclerosis Risk in Communities (ARIC) study from 1987 to 1989. They were followed, and incident CHD events were identified and verified. For the present study, we included 423 patients with CHD as cases and 479 noncases. FXIIIA Val34Leu polymorphism was determined by the single-strand conformational polymorphism method. There were no significant differences in the genotype frequencies between cases and noncases. The genotypes showed little association with known CHD risk factors. A weighted proportional hazards regression analysis adjusting for other risk factors confirmed no association of the genotypes with risk of CHD. This prospective study did not provide evidence of a reduced CHD risk for the FXIIIA 34Leu allele.

Key Words: factor XIII • factor XIIIA Val34Leu polymorphism • coronary heart disease

This article has been cited by other articles:

				F. Marin, R. Gonzalez-Conejero, P. Capranzano, T. A. Bass, V. Roldan, and D. J. Angiolillo Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1041 - 1057. [Abstract] [Full Text] [PDF]

				W.A. Boisvert, D.M. Rose, A. Boullier, O. Quehenberger, A. Sydlaske, K.A Johnson, L.K. Curtiss, and R. Terkeltaub Leukocyte Transglutaminase 2 Expression Limits Atherosclerotic Lesion Size Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 563 - 569. [Abstract] [Full Text] [PDF]

				F. Marin, R. Gonzalez-Conejero, K. W. Lee, J. Corral, V. Roldan, F. Lopez, F. Sogorb, J. Caturla, G. Y.H. Lip, and V. Vicente A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction J. Am. Coll. Cardiol., January 4, 2005; 45(1): 25 - 29. [Abstract] [Full Text] [PDF]

				H. Tammen, T. Mohring, M. Kellmann, A. Pich, H. H. Kreipe, and R. Hess Mass Spectrometric Phenotyping of Val34Leu Polymorphism of Blood Coagulation Factor XIII by Differential Peptide Display Clin. Chem., March 1, 2004; 50(3): 545 - 551. [Abstract] [Full Text] [PDF]

				C. Butt, H. Zheng, E. Randell, D. Robb, P. Parfrey, and Y.-G. Xie Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction Blood, April 15, 2003; 101(8): 3037 - 3041. [Abstract] [Full Text] [PDF]

				F. L Ruberg and J. Loscalzo Prothrombotic determinants of coronary atherothrombosis Vascular Medicine, November 1, 2002; 7(4): 289 - 299. [Abstract] [PDF]

				R. A. S. Ariens, T.-S. Lai, J. W. Weisel, C. S. Greenberg, and P. J. Grant Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms Blood, July 18, 2002; 100(3): 743 - 754. [Abstract] [Full Text] [PDF]